Acute Overexpression of Myc in Intestinal Epithelium Recapitulates Some but Not All the Changes Elicited by Wnt/β-Catenin Pathway Activation

Por Finch, Andrew J., Soucek, Laura, Junttila, Melissa R., Swigart, Lamorna Brown, Evan, Gerard I.
Publicado em 2009

Castration-Resistant Lgr5(+) Cells Are Long-Lived Stem Cells Required for Prostatic Regeneration

Por Wang, Bu-er, Wang, Xi, Long, Jason E., Eastham-Anderson, Jeff, Firestein, Ron, Junttila, Melissa R.
Publicado no Stem Cell Reports (2015)

Distinct thresholds govern Myc’s biological output in vivo

Por Daniel, J. Murphy, Junttila, Melissa R., Pouyet, Laurent, Karnezis, Anthony, Shchors, Ksenya, Bui, Duyen A., Brown-Swigart, Lamorna, Johnson, Leisa, Evan, Gerard. I.
Publicado em 2008

Selective activation of p53-mediated tumour suppression in high-grade tumours

Por Junttila, Melissa R., Karnezis, Anthony, Garcia, Daniel, Madriles, Francesc, Kortlever, Roderik M., Rostker, Fanya, Brown-Swigart, Lamorna, Pham, David M., Seo, Youngho, Evan, Gerard I., Martins, Carla P.
Publicado em 2010

Quantification of Tumor Burden in a Genetically Engineered Mouse Model of Lung Cancer by Micro-CT and Automated Analysis()

Por Barck, Kai H., Bou-Reslan, Hani, Rastogi, Ujjawal, Sakhuja, Timothy, Long, Jason E., Molina, Rafael, Lima, Anthony, Hamilton, Patricia, Junttila, Melissa R., Johnson, Leisa, Carano, Richard A.D.
Publicado no Transl Oncol (2015)

PME-1 protects ERK pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma

Por Puustinen, Pietri, Junttila, Melissa R., Vanhatupa, Sari, Sablina, Anna A., Hector, Melissa E., Teittinen, Kaisa, Raheem, Olayinka, Ketola, Kirsi, Lin, Shujun, Kast, Juergen, Haapasalo, Hannu, Hahn, William C., Westermarck, Jukka
Publicado em 2009

Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous

Por Chung, Wei-Jen, Daemen, Anneleen, Cheng, Jason H., Long, Jason E., Cooper, Jonathan E., Wang, Bu-er, Tran, Christopher, Singh, Mallika, Gnad, Florian, Modrusan, Zora, Foreman, Oded, Junttila, Melissa R.
Publicado no Proc Natl Acad Sci U S A (2017)

Transcription factor Etv5 is essential for the maintenance of alveolar type II cells

Por Zhang, Zhen, Newton, Kim, Kummerfeld, Sarah K., Webster, Joshua, Kirkpatrick, Donald S., Phu, Lilian, Eastham-Anderson, Jeffrey, Liu, Jinfeng, Lee, Wyne P., Wu, Jiansheng, Li, Hong, Junttila, Melissa R., Dixit, Vishva M.
Publicado no Proc Natl Acad Sci U S A (2017)

Manic Fringe deficiency imposes Jagged1 addiction to intestinal tumor cells

Por López-Arribillaga, Erika, Rodilla, Verónica, Colomer, Carlota, Vert, Anna, Shelton, Amy, Cheng, Jason H., Yan, Bing, Gonzalez-Perez, Abel, Junttila, Melissa R., Iglesias, Mar, Torres, Ferran, Albanell, Joan, Villanueva, Alberto, Bigas, Anna, Siebel, Christian W., Espinosa, LLuís
Publicado no Nat Commun (2018)

A stromal niche defined by expression of the transcription factor Wilms tumor 1 mediates programming and homeostasis of cavity-resident macrophages

Por Buechler, Matthew B., Kim, Ki-Wook, Onufer, Emily J., Williams, Jesse W., Little, Christine C., Dominguez, Claudia X., Li, Qingling, Sandoval, Wendy, Cooper, Jonathan E., Harris, Charles A., Junttila, Melissa R., Randolph, Gwendalyn J., Turley, Shannon J.
Publicado no Immunity (2019)

Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF–induced neutrophil recruitment

Por Phan, Vernon T., Wu, Xiumin, Cheng, Jason H., Sheng, Rebecca X., Chung, Alicia S., Zhuang, Guanglei, Tran, Christopher, Song, Qinghua, Kowanetz, Marcin, Sambrone, Amy, Tan, Martha, Meng, Y. Gloria, Jackson, Erica L., Peale, Franklin V., Junttila, Melissa R., Ferrara, Napoleone
Publicado em 2013

Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptation

Por Long, Jason E., Wongchenko, Matthew J., Nickles, Dorothee, Chung, Wei-Jen, Wang, Bu-er, Riegler, Johannes, Li, Ji, Li, Qingling, Sandoval, Wendy, Eastham-Anderson, Jeff, Modrusan, Zora, Junttila, Teemu, Carano, Richard A. D., Foreman, Oded, Yan, Yibing, Junttila, Melissa R.
Publicado no Cell Death Differ (2019)

Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1

Por Laine, Anni, Sihto, Harri, Come, Christophe, Rosenfeldt, Mathias T., Zwolinska, Aleksandra, Niemelä, Minna, Khanna, Anchit, Chan, Edward K., Kähäri, Veli-Matti, Kellokumpu-Lehtinen, Pirkko-Liisa, Sansom, Owen J., Evan, Gerard I., Junttila, Melissa R., Ryan, Kevin M., Marine, Jean-Christophe, Joensuu, Heikki, Westermarck, Jukka
Publicado em 2013

Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors

Por Merchant, Mark, Moffat, John, Schaefer, Gabriele, Chan, Jocelyn, Wang, Xi, Orr, Christine, Cheng, Jason, Hunsaker, Thomas, Shao, Lily, Wang, Stephanie J., Wagle, Marie-Claire, Lin, Eva, Haverty, Peter M., Shahidi-Latham, Sheerin, Ngu, Hai, Solon, Margaret, Eastham-Anderson, Jeffrey, Koeppen, Hartmut, Huang, Shih-Min A., Schwarz, Jacob, Belvin, Marcia, Kirouac, Daniel, Junttila, Melissa R.
Publicado no PLoS One (2017)

Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors

Por Merchant, Mark, Moffat, John, Schaefer, Gabriele, Chan, Jocelyn, Wang, Xi, Orr, Christine, Cheng, Jason, Hunsaker, Thomas, Shao, Lily, Wang, Stephanie J., Wagle, Marie-Claire, Lin, Eva, Haverty, Peter M., Shahidi-Latham, Sheerin, Ngu, Hai, Solon, Margaret, Eastham-Anderson, Jeffrey, Koeppen, Hartmut, Huang, Shih-Min A., Schwarz, Jacob, Belvin, Marcia, Kirouac, Daniel, Junttila, Melissa R.
Publicado no PLoS One (2018)

Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody

Por Staflin, Karin, Zuch de Zafra, Christina L., Schutt, Leah K., Clark, Vanessa, Zhong, Fiona, Hristopoulos, Maria, Clark, Robyn, Li, Ji, Mathieu, Mary, Chen, Xiaocheng, Johnston, Jennifer, Low, Justin, Ybarra, Ryan, Slaga, Dionysos, Yang, Jihong, Ovacik, Meric, Dybdal, Noël O., Totpal, Klara, Junttila, Melissa R., Ellerman, Diego, Lee, Genee, Dennis, Mark S., Prell, Rodney, Junttila, Teemu T.
Publicado no JCI Insight (2020)

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

Por Catenacci, Daniel V.T., Junttila, Melissa R., Karrison, Theodore, Bahary, Nathan, Horiba, Margit N., Nattam, Sreenivasa R., Marsh, Robert, Wallace, James, Kozloff, Mark, Rajdev, Lakshmi, Cohen, Deirdre, Wade, James, Sleckman, Bethany, Lenz, Heinz-Josef, Stiff, Patrick, Kumar, Pankaj, Xu, Peng, Henderson, Les, Takebe, Naoko, Salgia, Ravi, Wang, Xi, Stadler, Walter M., de Sauvage, Frederic J., Kindler, Hedy L.
Publicado no J Clin Oncol (2015)

RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases

Por Patel, Snahel, Webster, Joshua D., Varfolomeev, Eugene, Kwon, Youngsu C., Cheng, Jason H., Zhang, Juan, Dugger, Debra L., Wickliffe, Kate E., Maltzman, Allie, Sujatha-Bhaskar, Swathi, Bir Kohli, Pawan, Ramaswamy, Sreema, Deshmukh, Gauri, Liederer, Bianca M., Fong, Rina, Hamilton, Greg, Lupardus, Patrick, Caplazi, Patrick, Lee, Wyne P., van Lookeren Campagne, Menno, Johnson, Adam, McKenzie, Brent S., Junttila, Melissa R., Newton, Kim, Vucic, Domagoj
Publicado no Cell Death Differ (2019)